Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone or Tirzepatide in Normal-weight Diabetes
NCT06657209Phase 4Recruiting
- Sponsor
- Stanford University
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirzepatide and pioglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Stanford University. Primary endpoints: Insulin resistance, Adipocyte function and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
tirzepatidepioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06657209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657209.